medigraphic.com
Colegio de Medicina Interna de México.

2015, Número 4

<< Anterior Siguiente >>

Med Int Mex 2015; 31 (4)


Consenso multidisciplinario de prevención, diagnóstico y tratamiento de la obesidad en el varón joven y maduro

Pliego-Reyes CL, Alcántar-Ramírez J, Cárdenas-Cejudo A, Díaz-Jiménez K, Morales-Andrade E, Ramírez-Wiella G, Ríos-Martínez B, Sánchez-Lío KI, Tenorio-Aguirre K, Torres-Viloria A

Idioma: Español
Referencias bibliográficas: 90
Paginas: 414-433
Archivo PDF: 601.86 Kb.


RESUMEN

Antecedentes: la obesidad es el principal factor de riesgo modificable de enfermedades crónicas no trasmisibles en todo el mundo; en México, el sobrepeso y la obesidad son una epidemia con graves repercusiones para el sistema de salud, por eso es prioritario tomar acciones de prevención, diagnóstico oportuno y tratamiento adecuado, individualizado e interdisciplinario.
Objetivo: homologar y aplicar conceptos de la práctica clínica basada en evidencia para prevención, diagnóstico y tratamiento de la obesidad en individuos masculinos de 20 a 65 años de edad.
Material y método: consenso multidisciplinario (medicina interna, endocrinología, cirugía, psicología, nutrición, actividad física y salud pública). Se redactó un documento primario y, con base en éste, cada médico especialista actualizó de manera específica un tema y estableció la evidencia, el grupo la enriqueció y adaptó a las necesidades de la población nacionales y aprobó por unanimidad el escrito final del documento.
Resultados: la obesidad es una enfermedad multifactorial derivada de la compleja interacción entre el ambiente y el individuo que acarrea un conjunto de comorbilidades que causan disminución de la expectativa y calidad de vida; el tratamiento debe ser multidisciplinario: médico, nutricional y psicológico, con el propósito de influir, desde la prevención, en el tratamiento temprano.
Conclusiones: las recomendaciones de este consenso se basan en los mejores niveles de evidencia de las guías de tratamiento establecidas, en ensayos clínicos controlados y en guías estandarizadas para población adulta con obesidad, y se enriquecieron con la experiencia de cada participante.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales. 2a ed. Cuernavaca, México: Instituto Nacional de Salud Pública 2013.

  2. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza-Tobías A, Rivera-Dommarco JA. Prevalencia de obesidad en adultos mexicanos, ENSANUT 2012. Salud Pública Mex 2013;55:151-160.

  3. Rtveladze K, Marsh T, Barquera S, et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutrition 2013:1-7.

  4. Hernández M, Ruiz V. Obesidad, una epidemia mundial. Implicaciones de la genética. Rev Cubana Invest Bioméd 2007;26:1-10.

  5. McCarthy MI, Feero WG, Guttmacher AE. Genomics, type 2 diabetes and obesity. N Engl J Med 2010;363:2339-2350.

  6. López-Alarcón MG, Rodríguez-Cruz M. Epidemiología y genética del sobrepeso y la obesidad. Perspectiva en México en el contexto mundial. Bol Med Hosp Infant Méx 2008;65:421-430.

  7. LeBlanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Screening for and management of obesity and overweight in adults. Evidence Report No. 89 AHRQ 2011.

  8. Harder T, Bergmann R, Kallischnigg G, Plagemann A. Duration of breastfeeding and risk of overweight: a metaanalysis. Am J Epidem 2005;162:397-403.

  9. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003;289:1785-1791.

  10. Popkin BM, Adair LS, Ng SW. Global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev 2012;70:3-21.

  11. Rivera J, Muñoz-Hernández O, Rosas M. Consumo de bebidas para una vida saludable: Recomendaciones para la población mexicana. Am J Clin Nutr 2006;83:529-542.

  12. Barrera C, Ávila J, Cano E. Guía de práctica clínica para prevención, diagnóstico y tratamiento del sobrepeso y la obesidad exógena. Gac Méd Méx 2010;146:397-407.

  13. Norma Oficial Mexicana NOM-008-SSA3-2010 Para el tratamiento integral del sobrepeso y la obesidad.

  14. Barquera S, Campos-Nonato I, Rojas R, Rivera J. Obesidad en México: epidemiología y políticas de salud para su control y prevención. Gac Méd Méx 2010;146:397-407.

  15. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of metabolic syndrome. International Diabetes Federation 2006:1-23.

  16. Waumsley J, Atter N, Boyle S, Buckroyd J, et al. Obesity in the UK: a psychological perspective. Obesity Working Group 2011. Br Psychol Soc 2011:1-84.

  17. Barrera-Cruz A, Ávila-Jiménez L, Cano-Pérez E, Molina-Ayala MA, et al. Guía de práctica clínica. Prevención, diagnóstico y tratamiento del sobrepeso y la obesidad exógena. Rev Med Inst Mex Seguro Soc 2013;51:344-357.

  18. Lin HY, Huang CK, Tai CM, Lin HY, et al. Psychiatric disorders of patients seeking obesity treatment. BMC Psychiatry 2013;13:1.

  19. Ríos-Martínez BP, Rangel-Rodríguez G, Pedraza-Moctezuma LG. How do the obese persons perceive their overall health? Rev Med Inst Mex Seg Soc 2013;51:390-395.

  20. Bray GA. Obesity is a chronic, relapsing neurochemical disease. Int J Obes 2004;28:34-38.

  21. LeBlanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care–relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:434-447.

  22. Intervenciones de cambio en el comportamiento de los profesionales de la salud y la organización de la atención para promover la reducción de peso en adultos con sobrepeso y obesos (Revisión Cochrane traducida). Cochrane Database of Systematic Reviews 2010 Issue 12. Art. No.: CD000984. DOI: 10.1002/14651858.CD000984.

  23. Naci H, Ioannidis John P. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:1-14.

  24. Kushner RF, Sorensen KW. Lifestyle medicine: the future of chronic disease management. Curr Opin Endocrinol Diabetes Obes 2013;20:389-395.

  25. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2013;1-70.

  26. Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011;365:1959-1968.

  27. O’Rourke P, Kenardy J. Psychological interventions for overweight or obesity. Cochrane Database of Systematic Review 2005;2:CD003818.

  28. Donnelly JE, Blair SN, Jakicic JM, Manore MM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459-471.

  29. Arrizabalaga JJ, Calañas-Continente A, Vidal J, Masmiquel L, et al. Guía de práctica clínica para el manejo del sobrepeso y la obesidad en personas adultas. Endocrinol Nutr 2003;50:1-38.

  30. Cho S-H, Lee J-S, Thabane L, Lee J. Acupuncture for obesity: a systematic review and meta-analysis. Int J Obes 2009;33:183-196.

  31. Lacey JM, Tershakovec AM, Foster GD. Acupuncture for the treatment of obesity: a review of the evidence. Int J Obes 2003;27:419-427.

  32. Lira-García C, Souto-Gallardo M, Bacardí-Gascón M, Jiménez-Cruz A. Revisión de la efectividad de los ingredientes de productos alternativos para la pérdida de peso. Rev Salud Púb 2008;10:818-830.

  33. Pi-Sunyer FX, Becker DM, Bouchard C, Carleton RA, et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. National Institutes of Health. Obes Res 1998;98:1-228.

  34. Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis 2014;56:465-472.

  35. Yumuk V, Frühbeck G, Oppert JM, Woodward E, Toplak H. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts 2014;7:96-101.

  36. Fitch A, Everling L, Fox C, Goldberg J, et al. Institute for clinical systems improvement. Prevention and management of obesity for adults 2013.

  37. Prevención, diagnóstico y tratamiento del sobrepeso y la obesidad exógena. Guía de práctica clínica 2011. Catálogo maestro de guías de práctica clínica: IMSS-046-08.

  38. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86.

  39. Kelly EM, Tungol AA, Wesolowicz LA. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. J Manag Care Pharm 2013;19:642-654.

  40. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012;125:1695-1703.

  41. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26:262-273.

  42. Munro JF, MacCuish AD, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;1:352-354.

  43. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:920-926.

  44. Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003;35:86-91.

  45. Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075-1081.

  46. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-1530.

  47. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-572.

  48. Allison DB, Gadde KM, Garvey WT, Peterson CA, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342.

  49. Gadde KM, Allison DB, Ryan DH, Peterson CA, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352.

  50. Montastruc G, Favreliere S, Sommet A, Pathak A, et al. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2010;69:287-294.

  51. Yoshida T, Umekawa T, Wakabayashi Y, et al. Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis. Clin Exp Pharmacol Physiol 1996;23:476-482.

  52. Morin R, Lonngi G, Alcaraz R, Rosas DE. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses. Med Int Mex 2001;17:260-271.

  53. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-1825.

  54. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011;13:169-180.

  55. Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994;18:129-135.

  56. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-546.

  57. da Silva C, dos Santos J, Satie Takahashi C. An evaluation of the genotoxic and cytotoxic effects of the anti obesity drugs sibutramine and fenproporex. Hum Exp Toxicol 2010;29:187-197.

  58. Wadden TA, Foreyt JP, Foster GD, Hill JO, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-120.

  59. Astrup A, Carraro R, Finer N, Harper A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012;36:843-854.

  60. Lim RB, Blackburn GL, Jones DB. Benchmarking best practices in weight loss surgery. Curr Probl Surg 2010;47:79-174.

  61. Vu L, Switzer NJ, De Gara C, Karmali S. Surgical Interventions for obesity and metabolic disease. Best Pract Res Clin Endocrinol Metab 2013;27:239-246.

  62. Young T, Palta M, Dempsey J, et al. The occurrence of sleepdisordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235.

  63. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleepdisordered breathing. JAMA 2000;284:3015-3021.

  64. Horner RL, Mohiaddin RH, Lowell DG, Shea SA, et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur Respir J 1989;2:613-622.

  65. Sebastian JC. Respiratory physiology and pulmonary complications in obesity. Best Pract Res Clin Endocrinol Metab 2013;27:157-161.

  66. Epstein LJ, Kristo D, Strollo PJ Jr., Friedman N, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009;5:263-276.

  67. Tuomilehto HP, Seppä JM, Partinen MM, Peltonen M, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009;179:320-327.

  68. Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008;5:218-225.

  69. Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004;116:1-7.

  70. Mokhlesi B. Obesity hypoventilation syndrome: a state-ofthe- art review. Respir Care 2010;55:1363-1365.

  71. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097-1105.

  72. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Prevention Program (DPP) Research Group. Diabetes Care 2002;25:2165-2171.

  73. Standards of medical care in diabetes. American Diabetes Association. Diabetes Care 2014;37:14-80.

  74. Johnson WD, Brashear MM, Gupta AK, Rood JC, Ryan DH. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med 2011;124:931-938.

  75. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993;306:117-123.

  76. Huang Z, Willett WC, Manson JE, Rosner B, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998;128:81-88.

  77. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk; the Framingham experience. Arch Intern Med 2002;162:1867-1872.

  78. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension 2003;42:878-884.

  79. Modan M, Almog S, Fuchs Z, Chetrit A, et al. Obesity, glucose intolerance, hyperinsulinemia and response to antihypertensive drugs. Hypertension 1991;17:565-573.

  80. Kenchaiah S, Evans JC, Levy D, Wilson PW, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-313.

  81. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001;321:225-236.

  82. Fock KM, Khoo J. Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 2013;28:59-63.

  83. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.

  84. Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: The Chingford Study. J Rheumatol 1993;20:331-336.

  85. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992;116:535-539.

  86. Liel Y, Edwards J, Shary J, Spicer KM, et al. The effects of race and body habitus on bone mineral density of the radius, hip, and spine in premenopausal women. J Clin Endocrinol Metab 1988;66:1247-1250.

  87. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.

  88. Gallagher EJ, LeRoth D. Epidemiology and molecular mechanism tying obesity, diabetes and the metabolic syndrome with cancer. Diabetes Care 2013;36:233-239.

  89. Thomson CA, Stopeck AT, Bea JW, Cussler E, et al. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs reduced carbohydrate diets. Nutr Cancer 2010; 62:1142-1152.

  90. Dow CA, Thomson CA, Flatt SW, Sherwood NE, et al. Predictors of improvement in cardiometabolic risk factors with weight loss in women. J Am Heart Assoc 2013;2:000152.




2020     |     www.medigraphic.com